Global Treatment of Parathyroid Disease market size is predicted to grow from US$ 1494 million in 2025 to US$ 2175 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.

Global Treatment of Parathyroid Disease Market Size, Share and Analysis

The global Treatment of Parathyroid Disease market size is predicted to grow from US$ 1494 million in 2025 to US$ 2175 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031. The parathyroid glands are four small glands located in the neck that produce parathyroid hormone (PTH), which regulates the levels of calcium and phosphorus in the body. There are several drugs that can affect the function of the parathyroid gland or the levels of PTH in the body. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Treatment of Parathyroid Disease Industry Forecast looks at past sales and reviews total world Treatment of Parathyroid Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Treatment of Parathyroid Disease sales for 2025 through 2031. With Treatment of Parathyroid Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Treatment of Parathyroid Disease industry. This Insight Report provides a comprehensive analysis of the global Treatment of Parathyroid Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Parathyroid Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Treatment of Parathyroid Disease market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Parathyroid Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Parathyroid Disease. This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Parathyroid Disease market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Calcitriol &nbsp;&nbsp;&nbsp; Alfacalcidol &nbsp;&nbsp;&nbsp; Salmon Calcitonin &nbsp;&nbsp;&nbsp; Paricalcitol &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; CTTQ &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; Future Health Pharma &nbsp;&nbsp;&nbsp; KPC Pharmaceuticals &nbsp;&nbsp;&nbsp; Teva Pharmaceutical &nbsp;&nbsp;&nbsp; Nantong Huashan Pharmaceutical &nbsp;&nbsp;&nbsp; Teijin Pharma &nbsp;&nbsp;&nbsp; Kyowa Kirin &nbsp;&nbsp;&nbsp; Cheplapharm Arzneimittel &nbsp;&nbsp;&nbsp; Jiangsu Hengrui Pharmaceuticals &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Chongqing Yaoyou Pharmaceutical &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Hebei Renhe Yikang Pharmaceutical Key Questions Addressed in this Report What is the 10-year outlook for the global Treatment of Parathyroid Disease market? What factors are driving Treatment of Parathyroid Disease market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Treatment of Parathyroid Disease market opportunities vary by end market size? How does Treatment of Parathyroid Disease break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Treatment of Parathyroid Disease Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Treatment of Parathyroid Disease by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Treatment of Parathyroid Disease by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Treatment of Parathyroid Disease Segment by Type &nbsp;2.2.1 Calcitriol &nbsp;2.2.2 Alfacalcidol &nbsp;2.2.3 Salmon Calcitonin &nbsp;2.2.4 Paricalcitol &nbsp;2.2.5 Other &nbsp;2.3 Treatment of Parathyroid Disease Sales by Type &nbsp;2.3.1 Global Treatment of Parathyroid Disease Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Treatment of Parathyroid Disease Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Treatment of Parathyroid Disease Sale Price by Type (2020-2025) &nbsp;2.4 Treatment of Parathyroid Disease Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Clinic &nbsp;2.4.3 Other &nbsp;2.5 Treatment of Parathyroid Disease Sales by Application &nbsp;2.5.1 Global Treatment of Parathyroid Disease Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Treatment of Parathyroid Disease Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Treatment of Parathyroid Disease Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Treatment of Parathyroid Disease Breakdown Data by Company &nbsp;3.1.1 Global Treatment of Parathyroid Disease Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Treatment of Parathyroid Disease Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Treatment of Parathyroid Disease Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Treatment of Parathyroid Disease Revenue by Company (2020-2025) &nbsp;3.2.2 Global Treatment of Parathyroid Disease Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Treatment of Parathyroid Disease Sale Price by Company &nbsp;3.4 Key Manufacturers Treatment of Parathyroid Disease Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Treatment of Parathyroid Disease Product Location Distribution &nbsp;3.4.2 Players Treatment of Parathyroid Disease Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Treatment of Parathyroid Disease by Geographic Region &nbsp;4.1 World Historic Treatment of Parathyroid Disease Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Treatment of Parathyroid Disease Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Treatment of Parathyroid Disease Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Treatment of Parathyroid Disease Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Treatment of Parathyroid Disease Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Treatment of Parathyroid Disease Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Treatment of Parathyroid Disease Sales Growth &nbsp;4.4 APAC Treatment of Parathyroid Disease Sales Growth &nbsp;4.5 Europe Treatment of Parathyroid Disease Sales Growth &nbsp;4.6 Middle East & Africa Treatment of Parathyroid Disease Sales Growth 5 Americas &nbsp;5.1 Americas Treatment of Parathyroid Disease Sales by Country &nbsp;5.1.1 Americas Treatment of Parathyroid Disease Sales by Country (2020-2025) &nbsp;5.1.2 Americas Treatment of Parathyroid Disease Revenue by Country (2020-2025) &nbsp;5.2 Americas Treatment of Parathyroid Disease Sales by Type (2020-2025) &nbsp;5.3 Americas Treatment of Parathyroid Disease Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Treatment of Parathyroid Disease Sales by Region &nbsp;6.1.1 APAC Treatment of Parathyroid Disease Sales by Region (2020-2025) &nbsp;6.1.2 APAC Treatment of Parathyroid Disease Revenue by Region (2020-2025) &nbsp;6.2 APAC Treatment of Parathyroid Disease Sales by Type (2020-2025) &nbsp;6.3 APAC Treatment of Parathyroid Disease Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Treatment of Parathyroid Disease by Country &nbsp;7.1.1 Europe Treatment of Parathyroid Disease Sales by Country (2020-2025) &nbsp;7.1.2 Europe Treatment of Parathyroid Disease Revenue by Country (2020-2025) &nbsp;7.2 Europe Treatment of Parathyroid Disease Sales by Type (2020-2025) &nbsp;7.3 Europe Treatment of Parathyroid Disease Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Treatment of Parathyroid Disease by Country &nbsp;8.1.1 Middle East & Africa Treatment of Parathyroid Disease Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Treatment of Parathyroid Disease Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Treatment of Parathyroid Disease Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Treatment of Parathyroid Disease Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Treatment of Parathyroid Disease &nbsp;10.3 Manufacturing Process Analysis of Treatment of Parathyroid Disease &nbsp;10.4 Industry Chain Structure of Treatment of Parathyroid Disease 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Treatment of Parathyroid Disease Distributors &nbsp;11.3 Treatment of Parathyroid Disease Customer 12 World Forecast Review for Treatment of Parathyroid Disease by Geographic Region &nbsp;12.1 Global Treatment of Parathyroid Disease Market Size Forecast by Region &nbsp;12.1.1 Global Treatment of Parathyroid Disease Forecast by Region (2026-2031) &nbsp;12.1.2 Global Treatment of Parathyroid Disease Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Treatment of Parathyroid Disease Forecast by Type (2026-2031) &nbsp;12.7 Global Treatment of Parathyroid Disease Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 CTTQ &nbsp;13.1.1 CTTQ Company Information &nbsp;13.1.2 CTTQ Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.1.3 CTTQ Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 CTTQ Main Business Overview &nbsp;13.1.5 CTTQ Latest Developments &nbsp;13.2 Roche &nbsp;13.2.1 Roche Company Information &nbsp;13.2.2 Roche Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.2.3 Roche Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Roche Main Business Overview &nbsp;13.2.5 Roche Latest Developments &nbsp;13.3 Future Health Pharma &nbsp;13.3.1 Future Health Pharma Company Information &nbsp;13.3.2 Future Health Pharma Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.3.3 Future Health Pharma Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Future Health Pharma Main Business Overview &nbsp;13.3.5 Future Health Pharma Latest Developments &nbsp;13.4 KPC Pharmaceuticals &nbsp;13.4.1 KPC Pharmaceuticals Company Information &nbsp;13.4.2 KPC Pharmaceuticals Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.4.3 KPC Pharmaceuticals Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 KPC Pharmaceuticals Main Business Overview &nbsp;13.4.5 KPC Pharmaceuticals Latest Developments &nbsp;13.5 Teva Pharmaceutical &nbsp;13.5.1 Teva Pharmaceutical Company Information &nbsp;13.5.2 Teva Pharmaceutical Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.5.3 Teva Pharmaceutical Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Teva Pharmaceutical Main Business Overview &nbsp;13.5.5 Teva Pharmaceutical Latest Developments &nbsp;13.6 Nantong Huashan Pharmaceutical &nbsp;13.6.1 Nantong Huashan Pharmaceutical Company Information &nbsp;13.6.2 Nantong Huashan Pharmaceutical Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.6.3 Nantong Huashan Pharmaceutical Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Nantong Huashan Pharmaceutical Main Business Overview &nbsp;13.6.5 Nantong Huashan Pharmaceutical Latest Developments &nbsp;13.7 Teijin Pharma &nbsp;13.7.1 Teijin Pharma Company Information &nbsp;13.7.2 Teijin Pharma Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.7.3 Teijin Pharma Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Teijin Pharma Main Business Overview &nbsp;13.7.5 Teijin Pharma Latest Developments &nbsp;13.8 Kyowa Kirin &nbsp;13.8.1 Kyowa Kirin Company Information &nbsp;13.8.2 Kyowa Kirin Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.8.3 Kyowa Kirin Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Kyowa Kirin Main Business Overview &nbsp;13.8.5 Kyowa Kirin Latest Developments &nbsp;13.9 Cheplapharm Arzneimittel &nbsp;13.9.1 Cheplapharm Arzneimittel Company Information &nbsp;13.9.2 Cheplapharm Arzneimittel Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.9.3 Cheplapharm Arzneimittel Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Cheplapharm Arzneimittel Main Business Overview &nbsp;13.9.5 Cheplapharm Arzneimittel Latest Developments &nbsp;13.10 Jiangsu Hengrui Pharmaceuticals &nbsp;13.10.1 Jiangsu Hengrui Pharmaceuticals Company Information &nbsp;13.10.2 Jiangsu Hengrui Pharmaceuticals Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.10.3 Jiangsu Hengrui Pharmaceuticals Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview &nbsp;13.10.5 Jiangsu Hengrui Pharmaceuticals Latest Developments &nbsp;13.11 Novartis &nbsp;13.11.1 Novartis Company Information &nbsp;13.11.2 Novartis Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.11.3 Novartis Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Novartis Main Business Overview &nbsp;13.11.5 Novartis Latest Developments &nbsp;13.12 Chongqing Yaoyou Pharmaceutical &nbsp;13.12.1 Chongqing Yaoyou Pharmaceutical Company Information &nbsp;13.12.2 Chongqing Yaoyou Pharmaceutical Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.12.3 Chongqing Yaoyou Pharmaceutical Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Chongqing Yaoyou Pharmaceutical Main Business Overview &nbsp;13.12.5 Chongqing Yaoyou Pharmaceutical Latest Developments &nbsp;13.13 AbbVie &nbsp;13.13.1 AbbVie Company Information &nbsp;13.13.2 AbbVie Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.13.3 AbbVie Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 AbbVie Main Business Overview &nbsp;13.13.5 AbbVie Latest Developments &nbsp;13.14 Hebei Renhe Yikang Pharmaceutical &nbsp;13.14.1 Hebei Renhe Yikang Pharmaceutical Company Information &nbsp;13.14.2 Hebei Renhe Yikang Pharmaceutical Treatment of Parathyroid Disease Product Portfolios and Specifications &nbsp;13.14.3 Hebei Renhe Yikang Pharmaceutical Treatment of Parathyroid Disease Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Hebei Renhe Yikang Pharmaceutical Main Business Overview &nbsp;13.14.5 Hebei Renhe Yikang Pharmaceutical Latest Developments 14 Research Findings and Conclusion

Report	Global Treatment of Parathyroid Disease Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI49815

Buyer Information

Order Summary